Private
How Much Damage Have Vaccines Done to Society? - A Midwestern Doctor
Superb piece by a Midwesterm Doctor:
https://www.midwesterndoctor.com/p/how-much-damage-have-vaccines-done
Powerful and worth your time. Would that physicians would awaken to the evil they participate in...
Important Article - Please do not comply - do not enable
"College math professor validates my survey conclusions: vaccines ARE the main cause of chronic diseases
Confirmed: vaccines are a public health disaster because they are the #1 cause of chronic disease. When will the medical community admit their error?"
https://kirschsubstack.com/p/college-math-professor-validates
.And, excellent interview with Ed Dowd:..
https://usawatchdog.com/government-media-pretending-massive-health-crisis-not-going-on-ed-dowd/
-
Pediatric Pulmonology, Allergy for children
United States
Dear Roger Price, Thanks for the website link. I signed up to learn more. Health Care and Medical Care are different things, arent' they. Much of Health Care (the methods of avoiding disease) can be free: Better nutrition choices, better sleep, better exercise, better stress avoidance. But some cost money-- dental and vaccines for example. Figuring out the financing of this, without coercion, will be interesting. Thank you.
__reactions__ -
-
General Medicine
France
Cher Brendan May ,
le problème est la temporalité.3 crises épileptiques dans les 8 jours suivant la vaccination chez des non epileptiques vierges de tout atcd de covid avéré.2 encéphalopathies post vaccinales ? anthony RIO INTERNE DE 24 ANS DCD A NANTES ASTRA ZENECA.....ET POURQUOI PAS LES vaccins.VIOXX 6 A 8 OOO décès en FRANCE
LE SURVECTOR UNE HEPATITE POUR 270 PATIENTS TRAITES et des problèmes d'addiction... ISOMERIDE MEDIATOR.....
nous pouvons nous poser quelques questions meme si elles sont dérangeantes.5 lymphomes et leucémies dont 3 dcd des AVC 3 OAP CHEZ DES JEUNES DE 40 ANS EN 2 ANS 5 PR 14 PPR 16 EMBOLIES PULMONAIRES.37 ans d'exercice du jamais vu..pourquoi ne pas se poser de questions. des effets indésirables chez des persones n'ayant pas contracté la malasdie pour certains et les non vaccinés non malades
__reactions__ -
Psychiatry
Canada
Can someone please go through this string and delete the multiple copies of each single comment that seem to be there.
It seems that cancer rates have gone up, but it could be due to many factors, Covid itself, people's not seeking treatment as early as they might have otherwise, dietary and other changes while stuck at home, etc. etc.
There will be risks to the vaccine, but are they greater than the risk of not being vaccinated? This will likely change from one age group to another. We need research, not speculation about individual, or a few cases, that could well be just coincidence. So many people had the vaccine that you would expect to see cases like this by chance. If it isn't by chance then you need much more than a few individual examples to find any pattern.
As for the physician who said he or she cannot stand science and scientists, then I assume they are not actually a physician. To qualify as a physician you train as a scientist to some extent, even if all you do is keep up to date. Without that knowledge you have no way of understanding various papers and knowing which ones are likely valid to your practice, and which had poor research methodology and therefore should not be given as much consideration.
__reactions__
American Association for Cancer Research, April 5-10
The annual meeting of the American Association for Cancer Research was held this year from April 5 to 10 in San Diego, drawing approximately 19,000 participants from around the world, including scientists, cancer survivors, clinicians, allied health professionals, and industry professionals. The conference highlighted recent advances in the treatment, management, and prevention of cancer.
As part of the phase I/II PETRA multicenter clinical trial, Timothy A. Yap, M.B.B.S., Ph.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues found that saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), is associated with favorable efficacy and safety among patients with certain homologous recombination repair (HRR)-deficient breast cancers.
The investigators evaluated the safety and efficacy of saruparib among 306 patients with previously treated HRR-deficient breast, ovarian, pancreatic, or prostate cancer. They found that saruparib demonstrated a favorable safety and tolerability profile, with no unexpected safety findings. Adverse events leading to dose reduction or treatment discontinuation were infrequent and generally mild. Saruparib pharmacokinetics appeared to be linear and demonstrated robust target engagement. At the 60-mg once-daily dose, saruparib delivered promising efficacy, with deep and durable responses (overall response rate, duration of response, and median progression-free survival) observed in a heavily pretreated population of patients with breast cancer harboring HRR mutations (e.g., BRCA1, BRCA2, PALB2, RAD51C, and RAD51D). In collaboration with the U.S. Food and Drug Administration as part of Project Optimus, saruparib 60 mg once daily was established as the optimal recommended monotherapy dose to maximize efficacy and tolerability.
"Saruparib is a first-in-class, potent new-generation PARP inhibitor with high selectivity for PARP1. Saruparib has a wide therapeutic index, superior pharmacokinetic/pharmacodynamic properties, and efficacy compared with approved PARP inhibitors, and is conveniently administered as a once-daily dose," Yap said. "The favorable safety profile of saruparib together with the low rate of dose reduction compared with approved PARP inhibitors may allow patients to remain on treatment longer at an optimal dose with superior drug exposures and maximal target engagement, which could lead to improved efficacy."
The study was funded by AstraZeneca, the manufacturer of saruparib.
In another study, Edward Cliff, M.B.B.S., M.P.H., of Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues found that more than five years after a cancer drug goes through accelerated approval, more than half of drug-indication pairs have yet to demonstrate clinical benefit.
The authors performed a cohort study of cancer drugs granted accelerated approval from 2013 to 2017. The investigators found that 41 percent (19/46) did not improve overall survival or quality of life in confirmatory trials after more than five years of follow-up. Results were not yet available for another 15 percent (seven of 46). Among drugs converted to regular approval, 60 percent (29/48) of conversions relied on surrogate measures.
"Although accelerated approval can be useful, some cancer drugs do not end up demonstrating benefit in extending patients' lives or improving their quality of life," Cliff said. "Clinicians should consider and inform patients about the uncertainty of clinical benefit when offering novel cancer therapies."
The study was funded by Arnold Ventures.
Ruiyi Tian, M.P.H., of the Washington University School of Medicine in St. Louis, and colleagues found that accelerated aging is becoming increasingly common in recent birth cohorts.
The authors aimed to identify potential reasons for the rise in incidence of early-onset cancers among recent birth cohorts. Data were leveraged from around 150,000 participants in the U.K. Biobank to answer two questions: (1) whether recent birth cohorts are experiencing more accelerated aging than previous birth cohorts and (2) whether accelerated aging is associated with early-onset cancers. The researchers found that the phenomenon of accelerated aging is becoming increasingly common in recent birth cohorts. This may serve as an independent risk factor or a biological mediator for various environmental and lifestyle risk factors, leading to early-onset cancer.
"At the current stage, more validation studies of our findings across diverse populations, as well as mechanistic investigations, are required before these insights can be applied in clinical settings," Tian said. "However, it is imperative for recent generations to become more health conscious."
AACR: At-Home HPV Testing Boosts Cervical Cancer Screening Participation
FRIDAY, April 12, 2024 (HealthDay News) -- Mailed at-home self-sampling for human papillomavirus testing increases cervical cancer screening participation in underscreened populations by almost threefold, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
AACR: Novel Personalized Vaccine Feasible for Head and Neck Cancer
TUESDAY, April 9, 2024 (HealthDay News) -- The novel viral-based personalized cancer vaccine, TG4050, which encodes up to 30 patient- and tumor-specific sequences is feasible and safe for patients with resected head and neck squamous cell carcinoma, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
AACR: Accelerated Aging Linked to Incidence of Early-Onset Cancer
TUESDAY, April 9, 2024 (HealthDay News) -- Accelerated aging is increasing and is associated with an increased incidence of early-onset solid tumors, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
AACR: Exosome-Based miRNA Assay Can Detect Pancreatic Cancer
MONDAY, April 8, 2024 (HealthDay News) -- An exosome-based liquid biopsy assay can distinguish patients with pancreatic ductal adenocarcinoma from healthy donors, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
AACR: Little Benefit Seen for Cancer Drugs Given Accelerated Approval
MONDAY, April 8, 2024 (HealthDay News) -- Most cancer drugs granted accelerated approval do not demonstrate clinical benefit, according to a study published online April 7 in the Journal of the American Medical Association to coincide with the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 (HealthDay News) -- For patients with gastric/gastroesophageal junction adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
Copyright © 2020 HealthDay. All rights reserved.
2011 to 2021 Saw Increase in Vaccination Timeliness for Infants
MONDAY, April 15, 2024 (HealthDay News) -- From 2011 to 2021, there was an increase in vaccination timeliness among U.S. children aged 0 to 19 months, according to a study published online April 12 in JAMA Network Open.
Sophia R. Newcomer, Ph.D., M.P.H., from the University of Montana in Missoula, and colleagues conducted a cross-sectional study analyzing nationally representative data from the 2011 to 2021 National Immunization Survey-Child (NIS-Child) to measure vaccination timeliness among U.S. children aged 0 to 19 months. The surveys included 179,154 children, of whom 31.4, 32.4, and 30.2 percent lived above the federal poverty level with more than $75,000 in annual family income, lived at or above the poverty level with $75,000 or less in annual family income, and lived below the poverty level, respectively.
The researchers observed a decrease in the median average days undervaccinated for the combined seven-vaccine series, from 22.3 days in the 2011 survey to 11.9 days in the 2021 survey. There was an increase seen in the prevalence of on-time receipt of the combined seven-vaccine series, from 22.5 to 35.6 percent. The mean annual increase in on-time vaccination was 4.6, 2.8, and 2.0 percent for children with more than $75,000 in annual family income, for children living at or above the poverty level with $75,000 or less in annual family income, and for children living below the poverty level, respectively.
"Disparities in timely vaccination signal the need for an increased focus on access to and quality of immunization services for lower-income families and children without private health insurance," the authors write.
Copyright © 2020 HealthDay. All rights reserved.
Acute Cardiac Event Reported in 22.4 Percent of Seniors Hospitalized With RSV
MONDAY, April 15, 2024 (HealthDay News) -- More than 22 percent of older hospitalized adults with respiratory syncytial virus (RSV) infection experience an acute cardiac event, according to a study published online April 15 in JAMA Internal Medicine.
Rebecca C. Woodruff, Ph.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted a cross-sectional study examining surveillance data from the RSV Hospitalization Surveillance Network. To estimate the weighted period prevalence of acute cardiac events, cases of RSV infection in adults aged 50 years and older within 12 states over five RSV seasons were examined.
A total of 6,248 hospitalized adults with laboratory-confirmed RSV infection were included. The researchers found that the weighted estimated prevalence of experiencing a cardiac event was 22.4 percent, with weighted estimated prevalence of 15.8, 7.5, 1.3, 1.1, and 0.6 percent for acute heart failure, acute ischemic heart disease, hypertensive crisis, ventricular tachycardia, and cardiogenic shock, respectively. The risk for experiencing an acute cardiac event was higher for adults with underlying cardiovascular disease (33.0 versus 8.5 percent; adjusted risk ratio [aRR], 3.51). Of the hospitalized adults with RSV infection, 18.6 and 4.9 percent required intensive care unit (ICU) admission and died, respectively; those who experienced an acute cardiac event had higher risks for ICU admission and in-hospital death (aRRs, 1.54 and 1.77, respectively).
"Acute cardiac events contribute substantially to the burden of RSV disease; whether RSV vaccination can prevent these complications is an important question as the impact of these vaccines is evaluated," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editor's Note (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
